Our recent outcomes and needs assessment data demonstrate a dramatic negative “awareness shift” of key treatment information among both hematologists and oncologists. Practice-changing data are now emerging so quickly, and in such great volume, that treating oncologists do not learn about new agents and integrate the latest data until much later in the drug development process and, in many cases, not until well after agents have been approved for use. In this White Paper, we highlight the key findings, and suggest innovative changes to CME offerings that recognize this deficit and could help mitigate these gaps and improve patient care. Although this analysis is specific to our hematology/oncology data, we believe the same lessons apply in areas such as rheumatology/immunology, virology, and other therapeutic areas where the pace of change is increasing as well.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.